Cargando…

Exposure–Bleeding Count Modeling of Emicizumab for the Prophylaxis of Bleeding in Persons with Hemophilia A with/Without Inhibitors Against Factor VIII

BACKGROUND AND OBJECTIVE: Emicizumab is a monoclonal antibody that bridges activated coagulation factor IX and factor X to restore effective hemostasis in persons with hemophilia A. It is indicated for routine prophylaxis of bleeding episodes in persons with hemophilia A. The aim of the present stud...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jonsson, Fredrik, Schmitt, Christophe, Petry, Claire, Mercier, Francois, Frey, Nicolas, Retout, Sylvie
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2021
Materias:	Original Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8249270/ https://www.ncbi.nlm.nih.gov/pubmed/33709296 http://dx.doi.org/10.1007/s40262-021-01006-0

Ejemplares similares

Population Pharmacokinetic Analysis and Exploratory Exposure–Bleeding Rate Relationship of Emicizumab in Adult and Pediatric Persons with Hemophilia A
por: Retout, Sylvie, et al.
Publicado: (2020)

Serious bleeds in pediatric persons with hemophilia A on emicizumab prophylaxis
por: Garcia, Jessica, et al.
Publicado: (2023)

Pharmacokinetics and Pharmacodynamics of Emicizumab in Persons with Hemophilia A with Factor VIII Inhibitors: HAVEN 1 Study
por: Schmitt, Christophe, et al.
Publicado: (2021)

Efficacy of emicizumab is maintained throughout dosing intervals for bleed prophylaxis
por: Pipe, Steven W., et al.
Publicado: (2023)

Real-World Data on Bleeding Patterns of Hemophilia A Patients Treated with Emicizumab
por: Levy-Mendelovich, Sarina, et al.
Publicado: (2021)

Emicizumab initiation and bleeding outcomes in people with hemophilia A with and without inhibitors: A single‐center report
por: Warren, Beth Boulden, et al.
Publicado: (2021)

Verification and Comparison of Chromogenic Factor VIII Activity Assays in Patients With Hemophilia Treated With and Without Emicizumab
por: Lee, Min Young, et al.
Publicado: (2023)

Emicizumab dose up‐titration in case of suboptimal bleeding control in people with haemophilia A
por: Schmitt, Christophe, et al.
Publicado: (2022)

Association between Sports Participation, Factor VIII Levels and Bleeding in Hemophilia A
por: Bukkems, Laura H., et al.
Publicado: (2022)

Emicizumab in children: bleeding episodes and outcome before and after transition to Emicizumab
por: Glonnegger, Hannah, et al.
Publicado: (2022)

Factor VIII inhibitors in hemophilia A treated with emicizumab: longitudinal follow-up of outcomes
por: Levy-Mendelovich, Sarina, et al.
Publicado: (2023)

A Model‐Based Framework to Inform the Dose Selection and Study Design of Emicizumab for Pediatric Patients With Hemophilia A
por: Yoneyama, Koichiro, et al.
Publicado: (2021)

Factor VIII activity and bleeding risk during prophylaxis for severe hemophilia A: a population pharmacokinetic model
por: Tiede, Andreas, et al.
Publicado: (2020)

Safety and efficacy of long‐term emicizumab prophylaxis in hemophilia A with factor VIII inhibitors: A phase 3b, multicenter, single‐arm study (STASEY)
por: Jiménez‐Yuste, Víctor, et al.
Publicado: (2022)

Relationship between factor VIII activity, bleeds and individual characteristics in severe hemophilia A patients
por: Abrantes, João A., et al.
Publicado: (2020)

Regression Analysis to Estimate the Factor VIII Activity of Patients with Hemophilia A Without Inhibitor who Received Emicizumab Therapy
por: Hatayama, Yuki, et al.
Publicado: (2022)

Emicizumab prophylaxis for people with hemophilia A: Waste estimation and the Brazilian perspective
por: Camelo, Ricardo Mesquita, et al.
Publicado: (2023)

Cerebellar hematoma in severe hemophilia with inhibitor on emicizumab prophylaxis: a case report
por: Albattat, Sami, et al.
Publicado: (2023)

Peri‐operative hemostatic management of tooth extraction in patients with hemophilia A, with and without inhibitors, receiving emicizumab prophylaxis
por: Yagyuu, Takahiro, et al.
Publicado: (2022)

Emicizumab Associated Rhabdomyolysis in Hemophilia A
por: Wilson, Joseph A., et al.
Publicado: (2020)

Model of Short- and Long-Term Outcomes of Emicizumab Prophylaxis Treatment for Persons with Hemophilia A
por: Zhou, Zheng-Yi, et al.
Publicado: (2020)

Utilization of Emicizumab in Acquired Factor VIII Deficiency
por: Hess, Kevin J., et al.
Publicado: (2020)

Correction of bleeding in experimental severe hemophilia A by systemic delivery of factor VIII-encoding mRNA
por: Russick, Jules, et al.
Publicado: (2020)

Untreated bleeds in people with hemophilia A in a noninterventional study and intrapatient comparison after initiating emicizumab in HAVEN 1–3
por: Callaghan, Michael U., et al.
Publicado: (2022)

Management of surgery in persons with hemophilia A receiving emicizumab prophylaxis: data from a national hemophilia treatment center
por: Cohen, Omri, et al.
Publicado: (2023)

Cost‐effectiveness of recombinant factor VIII Fc versus emicizumab for prophylaxis in adults and adolescents with haemophilia A without inhibitors in the UK
por: Kragh, Nana, et al.
Publicado: (2022)

Hemophilia prophylaxis adherence and bleeding using a tailored, frequency‐escalated approach: The Canadian Hemophilia Primary Prophylaxis Study
por: Dover, Saunya, et al.
Publicado: (2020)

Management of a High-Risk Surgery with Emicizumab and Factor VIII in a Child with a Severe Hemophilia A and Inhibitor
por: Lefèvre, Charles R., et al.
Publicado: (2021)

Effect of emicizumab prophylaxis on bone and joint health markers in people with haemophilia A without factor VIII inhibitors in the HAVEN 3 study
por: Kiialainen, Anna, et al.
Publicado: (2022)

Comparing Factor Use and Bleed Rates in U.S. Hemophilia A Patients Receiving Prophylaxis with 3 Different Long-Acting Recombinant Factor VIII Products
por: Simpson, Mindy L., et al.
Publicado: (2020)

Surgical outcomes in people with hemophilia A taking emicizumab prophylaxis: experience from the HAVEN 1-4 studies
por: Kruse-Jarres, Rebecca, et al.
Publicado: (2022)

Real-world experience of emicizumab prophylaxis in young children with hemophilia A: retrospective data from China
por: Liu, Guoqing, et al.
Publicado: (2022)

Management and Outcomes of Invasive Procedures in Individuals with Hemophilia A on Emicizumab Prophylaxis: A Single Center Experience
por: Rener, Karla, et al.
Publicado: (2023)

Disruptive technology and hemophilia care: The multiple impacts of emicizumab
por: Hermans, Cedric, et al.
Publicado: (2021)

P1616: EMICIZUMAB FOR THE MANAGEMENT OF ACQUIRED HEMOPHILIA A
por: Sridharan, Meera, et al.
Publicado: (2023)

Low immunogenicity of emicizumab in persons with haemophilia A
por: Schmitt, Christophe, et al.
Publicado: (2021)

Relationship between factor VIII levels and bleeding for rFVIII‐SingleChain in severe hemophilia A: A repeated time‐to‐event analysis
por: Bukkems, Laura H., et al.
Publicado: (2023)

Emicizumab prophylaxis in a Korean child with severe hemophilia A and high titer inhibitor: a case report
por: Ahn, Ji Hyun, et al.
Publicado: (2021)

Breakthrough Bleeding Episodes at Minimum and Improvement in Quality of Life in a Child with Severe Hemophilia A with Inhibitors Treated with Emicizumab: A Case Report from Chile
por: Abarca-Villaseca, Viviana, et al.
Publicado: (2021)

Traumatic Tonsillar Hemorrhage during Hemophilia A Treatment with Emicizumab
por: Inoue, Fumiya, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_h1nlu3vl381n7b8nsikor8d030